Bayer HealthCare AG
87 articles about Bayer HealthCare AG
-
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
1/10/2023
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.
-
LION-101 is a novel recombinant AAV being developed as a one-time intravenous infusion for the treatment of adult and adolescent patients with Limb-Girdle Muscular Dystrophy Type 2I/R9.
-
FDA Approves Bayer HealthCare AG's Gadavist® (gadobutrol) Injection As The First Magnetic Resonance Contrast Agent For Pediatric Patients Less Than 2 Years Of Age
1/5/2015
-
Bayer HealthCare AG Release: Phase 3 Investigational Trial Of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints In Subjects With Papulopustular Rosacea
7/24/2014
-
Bayer HealthCare Receives National Organization Of Rare Disorders (NORD) Honor At "Portraits Of Courage" Celebration
5/9/2014
-
Bayer HealthCare Introduces "Your Ride With A Legend" Educational Program For Horse Enthusiasts
4/25/2014
-
FDA Grants Orphan Drug Designation For Bayer HealthCare's Investigational Ciprofloxacin DPI (Dry Powder For Inhalation) For Treatment Of Non-Cystic Fibrosis Bronchiectasis
4/23/2014
-
Bayer HealthCare AG To Dump $138 Million In Beijing Facility
4/1/2014
-
Bayer HealthCare Launches Eight New Products To Treat Flea And Tick Infestations
3/12/2014
-
Bayer HealthCare AG's Seresto® Voted Best New Flea And Tick Control Product For Dogs In The 2014 Better Homes And Gardens Best New Product Awards
2/28/2014
-
Bayer HealthCare Statement
2/12/2014
-
Bayer HealthCare's Annihilator Polyzone® Makes Insect Control Easy All Season Long
1/29/2014
-
FDA Approves New Label Indications For Bayer HealthCare's Advantage Multi® (Imidacloprid + Moxidectin) In The U.S.
12/20/2013
-
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG Report Positive One-Year Results From Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema
8/8/2013
-
Bayer HealthCare Commences Hemophilia A Trial
7/8/2013
-
Bayer HealthCare AG Lays Off 50 at Medrad
5/10/2013
-
Bayer HealthCare AG: NDA for Riociguat Gets Priority Review
4/8/2013
-
Innovative Partnership Reduces Cost of Bayer HealthCare AG's Long-Acting Reversible Contraceptive Implant by More Than 50 Percent
2/27/2013
-
Bayer HealthCare Consumer Care Voluntarily Recalls 56 Lots of BRONKAID Caplets
12/10/2012
-
Bayer HealthCare Guilty of Breaching ABPI Codes
8/2/2012